Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.

Fibroblast growth factor receptor 4 (FGFR4) has been identified as a potential target for the treatment of hepatocellular carcinoma (HCC) with aberrant FGFR4 signaling because of its important role in HCC progression and development. Several FGFR4 inhibitors are under clinical development. Using a 7-azaindole scaffold, we discovered a series of novel selective and covalent FGFR4 inhibitors by performing a structure-based design approach. Representative compounds 24 and 30 exhibited potent FGFR4 inhibition and high selectivity among kinases. Western blot analysis showed that compounds 24 and 30 significantly inhibited the FGF19/FGFR4 signaling pathway in HuH-7 cells and effectively suppressed the proliferation of HuH-7 HCC cells and MDA-MB-453 breast cancer cells. Moreover, compound 30 exhibited significant in vivo antitumor activity in a mouse HuH-7 xenograft model. Thus, compound 30 and the 7-azaindole scaffold can be applied to develop anticancer agents for the treatment of cancers characterized by aberrant FGFR4 signaling.

[1]  Qiaomei Jin,et al.  Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma. , 2020, Bioorganic & medicinal chemistry.

[2]  J. Carpten,et al.  Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma. , 2020, Journal of medicinal chemistry.

[3]  W. Jahnke,et al.  Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. , 2020, Journal of medicinal chemistry.

[4]  J. McDonald,et al.  Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma. , 2020, ACS medicinal chemistry letters.

[5]  Yanmin Zhang,et al.  Recent advance in the development of novel, selective and potent FGFR inhibitors. , 2019, European journal of medicinal chemistry.

[6]  J. Smaill,et al.  Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. , 2019, ACS medicinal chemistry letters.

[7]  J. Smaill,et al.  Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. , 2018, Journal of medicinal chemistry.

[8]  Yikai Wang,et al.  Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping. , 2017, Bioorganic & medicinal chemistry letters.

[9]  Yong Xu,et al.  2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. , 2017, ACS medicinal chemistry letters.

[10]  P. Ross,et al.  Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma , 2015, Diseases.

[11]  H. Nakagama,et al.  FGF Receptors: Cancer Biology and Therapeutics , 2014, Medicinal research reviews.

[12]  C. Park,et al.  Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma , 2013, Digestive Diseases and Sciences.

[13]  D. French,et al.  Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models , 2012, PloS one.

[14]  M. Miyazaki,et al.  Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma , 2012, BMC Cancer.

[15]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[16]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[17]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[18]  V. P. Eswarakumar,et al.  Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.

[19]  T. Kang,et al.  Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. , 2014, Drug discovery today.

[20]  A. Ullrich,et al.  Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. , 2009, Journal of hepatology.